OS9 anticorps (AA 101-200) (HRP)

N° du produit ABIN759560

Détail du produit anti-OS9 anticorps (HRP)

Antigène: OS9 (Osteosarcoma Amplified 9, Endoplasmic Reticulum Lectin (OS9))

Épitope: AA 101-200

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp OS9 est conjugé à/à la HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Souris

Homologie: Human,Rat,Dog,Cow,Sheep,Horse,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human OS9

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Conseil sur la manipulation: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur OS9

Antigène: OS9 (Osteosarcoma Amplified 9, Endoplasmic Reticulum Lectin (OS9))

Autre désignation: OS9 (OS9 Produits)

Synonymes: anticorps OS-9, anticorps zgc:153838, anticorps 4632413K17Rik, anticorps AU022351, anticorps Os-9, anticorps ERLEC2, anticorps OS9, endoplasmic reticulum lectin, anticorps osteosarcoma amplified 9, endoplasmic reticulum lectin, anticorps amplified in osteosarcoma, anticorps OS9, anticorps os9, anticorps Os9

Sujet:

Synonyms: lied in osteosarcoma 9, amplied in osteosarcoma, OS-9, Os9, OS9_HUMAN, Protein OS-9.

Background: Lectin which functions in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). May bind terminally misfolded non-glycosylated proteins as well as improperly folded glycoproteins, retain them in the ER, and possibly transfer them to the ubiquitination machinery and promote their degradation. Possible targets include TRPV4.

ID gène: 10956

Pathways: Maintenance of Protein Location, SARS-CoV-2 Protein Interactome